CAR T in R/R MM: Key Takeaways and Pearls

Opinion
Video

Panelists discuss how successful implementation of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM) depends on early referral, coordinated care between academic and community centers, standardized protocols for patient management, and careful consideration of product selection and timing based on individual patient factors.

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts in this video
3 experts in this video
3 experts in this video
4 experts are featured in this series.
3 experts in this video
4 experts are featured in this series.
Related Content